CBD Regulation in 2026: Where the Market Stands and What Brands Can Say

CBD Regulation in 2026: Where the Market Stands and What Brands Can Say

The UK and EU CBD market has been a labyrinth of evolving regulations, promise, and considerable frustration for brand owners and manufacturers alike. As we hurtle towards 2026, a clearer albeit complex picture emerges, offering both challenges and opportunities for those committed to compliant innovation. This article will delve into the current regulatory landscape, dissecting the nuances that dictate product development, marketing claims, and the competitive edge in this burgeoning sector.

The UK’s Novel Food Pathway: A Steady, Not-So-Speedy Progress

The UK’s approach to CBD, largely driven by the Food Standards Agency (FSA), continues to be defined by the Novel Food authorisation process. As of early 2026, while a significant number of applications have been submitted, the number of fully authorised products remains relatively modest but is growing. The initial 31st March 2021 deadline for valid novel food applications created a bottleneck, and the subsequent FSA public list of compliant products has been a critical barometer for market access. Brands operating in the UK must ensure their CBD extracts originate from suppliers whose applications are on this list and, crucially, that their final product aligns with a fully authorised dossier.

Industry Data Snapshot: Recent market analysis by Prohibition Partners (Q4 2025 data points to an estimated £690 million UK CBD market by 2026, with consumer trust being a significant driver for growth. However, this growth is intrinsically linked to regulatory clarity and the removal of illicit products. The FSA's ongoing enforcement efforts, while sometimes slow, are gradually weeding out non-compliant players, paving the way for legitimate businesses.

Practical Manufacturing Insight: For contract manufacturers, this means rigorous due diligence of raw material suppliers. Certificates of Analysis (CoAs) are no longer sufficient; proof of novel food dossier inclusion and alignment with processing methodologies are paramount. Batch traceability from cultivation to finished product is non-negotiable. Furthermore, formulators must be meticulous in ensuring their final product specifications, especially regarding THC limits (currently <1mg per pack, non-detectable), consistently meet the FSA's stringent requirements. Any deviation could invalidate a product's compliance, leading to costly recalls and reputational damage.

EU's Diverse and Disjointed Landscape

Across the Channel, the EU's CBD regulatory framework remains considerably more fragmented than the UK. While the European Commission's 2020 ruling classifying CBD as a novel food was a pivotal moment, leading to a wave of applications, individual member states retain significant autonomy. This creates a patchwork of regulations where what's permissible in Germany might be problematic in France, or outright prohibited in others.

Germany: Often seen as a benchmark within the EU for medical cannabis, Germany's stance on CBD foods is generally aligned with the novel food principle. However, specific requirements around THC levels and marketing claims can vary.

France: Has seen a series of flip-flops, but the current position is generally accepting of CBD products derived from the whole plant, provided THC levels are non-detectable. However, the novel food pathway is still applicable for specific product categories.

Other Member States: Countries like Italy and Spain exhibit more liberal approaches, often allowing CBD in food supplements with fewer restrictions, while others, particularly in Eastern Europe, maintain stricter controls or outright bans on certain concentrations or product types.

Manufacturing Implications for EU Export: Brands targeting multiple EU markets must undertake extensive legal counsel for each specific country. This often necessitates bespoke formulations, labelling, and primary packaging to comply with individual member state laws. Contract manufacturers engaging in EU export must offer flexible production capabilities and a deep understanding of multi-jurisdictional compliance expertise. Testing protocols must meet the most stringent regulatory requirements across target markets, often going beyond basic cannabinoid profiling to include heavy metals, pesticides, and microbial contaminants.

What Brands Can Say: Navigating the Claims Minefield

This is arguably the most challenging aspect for CBD brands. Both the UK and EU prohibit unauthorised health claims for food supplements. The European Food Safety Authority (EFSA) has consistently rejected all health claims related to CBD due to insufficient scientific evidence that meets their rigorous standards for authorisation under the EU Nutrition and Health Claims Regulation (NHCR).

The 'Wellness' Tightrope: Brands are relegated to general 'wellness' type claims, focusing on product characteristics rather than physiological effects. Permissible language includes descriptions like 'relaxing herbal extract,' 'contributes to a sense of calm,' or 'supports general well-being,' provided these are not construed as specific health claims and do not imply medicinal benefits. Any mention of pain relief, anti-inflammatory properties, or sleep improvement is strictly off-limits unless backed by a specific product-specific medical authorisation, which is an entirely different and far more arduous pathway than novel foods.

Marketing Compliance: This extends to all communication channels – websites, social media, packaging, and advertising. Brands must rigorously self-regulate and train their marketing teams to avoid explicit or implicit health claims. The Advertising Standards Authority (ASA) in the UK is active in policing misleading claims, and non-compliance can lead to advertising bans and reputational damage.

Manufacturing Best Practice: For contract manufacturers, this means offering comprehensive label review services, guiding brands on permissible wording for ingredients lists, dosage instructions, and general product descriptions. Developing robust Quality Management Systems (QMS) that integrate marketing compliance checks is crucial to protect both the manufacturer and the brand.

The Future: Consolidation and Specialisation

As regulatory frameworks mature, 2026 is likely to see further market consolidation. Brands that have successfully navigated the novel food process and operate with transparent, compliant supply chains will thrive. The emphasis will shift from a 'wild west' mentality to one of reputable, science-backed product development. We anticipate an increased specialisation, with some brands focusing on specific delivery formats (e.g., tinctures, edibles, topicals) or target demographics.

The regulatory journey for CBD is far from over. However, for those prepared to invest in robust compliance, quality assurance, and consumer education, the rewards remain substantial. The market landscape in 2026 will favour the informed, the diligent, and the genuinely compliant.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.